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Background: Recent studies have proposed a new prognostic factor (metastatic lymph node ratio, or MLNR) for
patients with esophageal cancer (EC). However, to the best of our knowledge, there have been no studies
conducted to date regarding MLNR in elderly patients. The aim of this study was to determine the prognostic value
of MLNR staging compared with the 2010 American Joint Committee on Cancer (AJCC) N staging in elderly
patients with EC.
Methods: From January 2001 to December 2009, a retrospective analysis of 132 consecutive patients older
than 70 years of age with esophageal squamous cell carcinoma (ESCC) was conducted. Prognostic factors for
disease-specific survival were analyzed. Receiver operating characteristic curves were also plotted to verify the
accuracy of MLNR staging and N staging for survival prediction.
Results: The disease-specific survival rates of N0, N1, N2 and N3 patients according to the AJCC Cancer
Staging Manual Seventh Edition N staging were 65.5%, 42.9%, 22.2% and 0, respectively (N0 vs N1, P = 0.017;
N1 vsN2, = 0.050; N2 vs N3, P < 0.001). The disease-specific survival rates of MLNR0, MLNR1, MLNR2 and MLNR3 patients
were 65.5%, 45.0%, 21.1% and 0, respectively (MLNR0 vsMLNR1, P = 0.026; MLNR1 vs MLNR2, P = 0.033; MLNR2 vs
MLNR3, P = 0.015). The areas under the curve were 0.731 for the 2010 AJCC N staging and 0.737 for the MLNR staging.
Conclusion: MLNR is an independent predictor of survival in elderly patients with ESCC. MLNR staging predicts survival
after EC similarly to the 2010 AJCC N classifications and should be considered an alternative to current N staging.
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Esophageal cancer (EC) is the eighth most common type
of cancer worldwide. In China, EC is the fourth most
common cause of mortality, with 11 deaths per 100,000 in
2005 [1]. However, esophageal squamous cell carcinoma
(ESCC) accounts for most EC cases in China, in contrast to
the predominance of adenocarcinoma in the Western
world [2]. Although advances have occurred in multidiscip-
linary treatment, surgical resection remains the treatment
modality of choice. One of the main determinants of
survival for patients undergoing esophagectomy is nodal* Correspondence: Cdbzjzl@163.com
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reproduction in any medium, provided the orstatus. However, the best method of characterizing the
extent of local lymph node metastases remains an area of
controversy.
Recent studies have proposed a new prognostic factor
(metastatic lymph node ratio, or MLNR) for EC patients
[3-5]. Controversy exists concerning the optimal cutoff
points for the MLNR to predict overall survival. The
different study sizes, variable inclusion criteria and, most
important, unreliable statistical methods used to determine
the cutoff points between groups have contributed to this
controversy. However, to the best of our knowledge, there
have been no studies conducted to date regarding MLNR
in elderly patients with EC.
The aim of this study was to determine the prognostic
value of MLNR staging compared with the 2010 Americand. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Baseline characteristics of 132 patients with
ESCCa
Characteristics Cases (n, %)























TLN (mean ± SD, n) 22.7 ± 9.7
NMLN (mean ± SD, n) 2.2 ± 3.7
MLNR
MLNR0 (0) 58 (43.9)
MLNR1 (>0, ≤0.1) 40 (30.3)
MLNR2 (>0.1, ≤0.3) 19 (14.4)
MLNR3 (>0.3) 15 (11.4)
aESCC, esophageal squamous cell carcinoma; MLNR metastatic lymph node
ratio; NMLN, number of metastatic lymph nodes; TLN, total lymph node.
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by lymph nodes in elderly patients with ESCC.
Methods
Patients
We conducted a retrospective analysis of patients treated
from January 2001 to December 2009. The sample popu-
lation comprised 132 patients older than 70 years of age
with ESCC who underwent curative esophagectomy in
the Department of Thoracic Surgery, Zhejiang Cancer
Hospital, Hangzhou, China. Patients who had received
pre- and or postoperative chemotherapy and/or radio-
therapy were excluded. We also excluded patients withnon-ESCC and gastroesophageal junction carcinoma, as
well as patients who underwent surgical exploration
without curative esophagectomy.
All of the above patients were followed up by posting
letters or by telephone interviews. The last follow-up was
on 30 November 2011. The clinicopathological and follow-
up findings were collected and recorded in the database. All
subjects gave their written informed consent to the study
protocol, which was approved by the ethical committees of
Zhejiang Cancer Hospital, Hangzhou, China.
Surgery
All patients were treated with radical resection. The stand-
ard surgical approach consisted of a limited thoracotomy
on the right side and intrathoracic gastric reconstruction
(the Ivor Lewis procedure) for lesions at the middle or
lower third of the esophagus. Upper-third lesions were
treated by cervical anastomosis (the McKeown procedure).
In our institution, two types of lymphadenectomy were
carried out as a standard procedure for ESCC. The majority
of patients underwent two-field lymphadenectomy. In this
cohort of patients, thoracoabdominal lymphadenectomy
was performed, including the subcarinal, paraesophageal,
pulmonary ligament, diaphragmatic and paracardial lymph
nodes, as well as those located along the lesser gastric
curvature, the origin of the left gastric artery, the celiac
trunk, the common hepatic artery and the splenic artery.
Three-field lymphadenectomy was performed only if the
cervical lymph nodes were thought to be abnormal
upon preoperative evaluation. All of the patients
included in the study were restaged according to the
classification system of the seventh edition of the
American Joint Committee on Cancer (AJCC) Cancer
Staging Manual (AJCC Seventh Edition) [6].
Statistical analysis
Statistical evaluation was conducted using SPSS version
17.0 software (SPSS Inc, Chicago, IL, USA). MLNR was
defined as the ratio metastatic lymph nodes to total
lymph nodes, and it was categorized into four groups
(0,>0, ≤0.1, >0.1, ≤0.3 and >0.3) as described in a previ-
ous study [4]. As this series described the prognosis of eld-
erly patients with ESCC, a disease-specific survival
analysis would more appropriately indicate the impact of
the N classification system on cancer-related prognosis.
The disease-specific survival was calculated by using the
Kaplan–Meier method, and the difference was assessed by
using the logrank test. Univariate and multivariate ana-
lyses of Cox regression proportional hazards model were
performed to evaluate the prognostic parameters for sur-
vival. Spearman’s correlation coefficient was calculated to
assess the correlation related to MLNR. Receiver operat-
ing characteristic (ROC) curves were also plotted to verify
the accuracy of MLNR staging and 2010 AJCC N staging
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The baseline characteristics are shown in Table 1.
Among the 132 patients, 11 (8.3%) were women and 121
(91.7%) were men. Their mean age was 73.7 ± 2.6 years,
with an age range of 70 to 85 years. The most common
tumor locations were the middle and lower esophagus
(95.5%). Total lymph node (TLN) harvest was highly vari-
able (Figure 1A). A mean of 22.7 ± 9.7 nodes per patient
was found during pathologic review (range: 6 to 61 nodes).
The number of metastatic lymph nodes (NMLNs)
per case ranged from 0 to 26 nodes (mean: 2.2 ± 3.7
nodes) (Figure 1B). The mean MLNR was 0.10
(range: 0 to 0.80). Of the 132 patients, 58 (43.9%)
were classified as MLNR0, 40 (30.3%) as MLNR1, 19
(14.4%) as MLNR2 and 15 (11.4%) as MLNR3.
Prognostic factors
Univariate analyses were performed to assess the
predictive capability of each variable (Table 2). As
expected, vessel involvement (P = 0.029), perineural
invasion (P = 0.007), tumor grade (= 0.003), N stage
(P < 0.001) and MLNR stage (P < 0.001) were predictive of
survival. There were no significant differences in terms of
age, gender, tumor size or tumor location. Significant
factors were extracted for further analysis, which wasFigure 1 Histograms of the total (A) and metastatic (B) lymph nodesconducted by using the multivariate Cox proportional
hazards model to adjust for the effects of covariates
(Table 3). In that model, we demonstrated that tumor
grade (P = 0.003), N stage (P < 0.001) and MLNR
stage (P < 0.001) were independent prognostic factors.
However, better discrimination was found for the
AJCC Nstage than MLNR classification in terms of
hazard ratio (HR) (N2 vs N3).
Disease-specific survival
The disease-specific survival rate was 45.5%. The survival
curves developed according to the AJCC Seventh Edition
N staging system, and the MLNR staging data are shown
in Figure 2. The disease-specific survival rates of N0, N1,
N2 and N3 patients according to AJCC Seventh Edition N
staging were 65.5%, 42.9%, 22.2% and 0, respectively (N0 vs
N1, P = 0.017; N1 vs N2, P = 0.050; N2 vs N3, P < 0.001).
The disease-specific survival rates of MLNR0, MLNR1,
MLNR2, and MLNR3 patients were 65.5%, 45.0%, 21.1%
and 0, respectively (MLNR0 vs MLNR1, P = 0.026; MLNR1
vs MLNR2, P = 0.033; MLNR2 vs MLNR3, P = 0.015). The
survival rates were similar between patients with N0 and
N1 and those with MLNR0 and MLNR1, but the survival
rates differed significantly between N1 vs N2 and MLNR1
vsMLNR2 (P = 0.050 vs. P = 0.033).
Correlation related to MLNR
As expected, there was a positive correlation between
the MLNR and NMLN (r = 0.914, P < 0.001) (Figure 3A).among surgery cohorts in ESCC patients.
Table 2 Univariate Cox regression analysis of disease-specific survivala
Characteristics Cases (n, %) DSS (%) HR (95% CI) P value
Age (yr) 0.838
≤75 97 (73.5) 46.4 1.000
>75 35 (26.5) 42.9 1.055 (0.629 to 1.770)
Gender
Female 11 (8.3) 54.5 1.000 0.474
Male 121 (91.7) 44.6 1.394 (0.561 to 3.460)
Tumor size (cm) 0.081
≤5 91 (68.9) 52.7 1.000
>5 41 (31.1) 29.3 1.524 (0.950 to 2.443)
Tumor location 0.778
Upper 6 (4.5) 50.0 1.000
Middle 55 (41.7) 45.5 0.938 (0.286 to 3.081) 0.916
Lower 71 (53.8) 45.1 1.114 (0.344 to 3.613) 0.857
Histologic grade 0.073
Well 17 (12.9) 58.8 1.000
Moderately 81 (61.4) 48.1 1.587 (0.712 to 3.538) 0.259
Poorly 34 (25.7) 32.4 2.461 (1.053 to 5.752) 0.038
Vessel involvement 0.029
No 100 (75.8) 48.0 1.000
Yes 32 (24.2) 37.5 1.786 (1.061 to 3.007)
Perineural invasion 0.007
No 113 (85.6) 49.6 1.000
Yes 19 (14.4) 21.1 2.198 (1.240 to 3.894)
Tumor grade 0.003
T1 19 (14.4) 89.5
T2 16 (12.1) 68.8 4.319 (0.854 to 12.727) 0.069
T3 89 (67.4) 33.7 7.731 (2.868 to 14.844) 0.003
T4 8 (6.1) 25.0 10.551 (2.969 to 21.902) 0.001
TLN (nodes) 0.729
≤18 47 (35.6) 44.7 1.000
>18 85 (64.4) 45.9 0.905 (0.597 to 1.427)
N stage <0.001
N0 58 (43.9) 65.5 1.000
N1 42 (31.8) 42.9 2.059 (1.136 to 3.732) 0.017
N2 18 (13.7) 22.2 4.122 (2.047 to 8.299) <0.001
N3 14 (10.6) 0 19.108 (8.503 to 42.939) <0.001
MLNR stage <0.001
MLNR0 58 (43.9) 65.5
MLNR1 40 (30.3) 45.0 1.963 (1.070 to 3.602) 0.026
MLNR2 19 (14.4) 21.1 4.142 (2.902 to 8.202) <0.001
MLNR3 15 (11.4) 0 12.037 (5.866 to 24.698) <0.001
aCI, confidence interval; DSS, disease-specific survival; HR, hazard ratio.
Feng et al. World Journal of Surgical Oncology 2013, 11:162 Page 4 of 8
http://www.wjso.com/content/11/1/162
Table 3 Multivariate Cox regression analysis of
disease-specific survivala
Characteristics HR (95% CI) P value
Vessel involvement 0.667
No 1.000
Yes 0.868 (0.456 to 1.652)
Perineural invasion 0.205
No 1.000
Yes 1.555 (0.786 to 3.075)
Tumor grade 0.003
T1 1.000
T2 2.177 (0.474 to 6.841) 0.198
T3 4.190 (0.733 to 10.148) 0.090
T4 7.170 (1.909 to 15.503) 0.010
N stage <0.001
N0 1.000
N1 1.315 (0.709 to 2.440) 0.385
N2 2.366 (1.143 to 4.897) 0.020
N3 16.474 (6.390 to 42.468) <0.001
MLNR stage <0.001
MLNR0 1.000
MLNR1 1.173 (0.625 to 2.203) 0.619
MLNR2 2.678 (1.320 to 5.433) 0.006
MLNR3 7.860 (3.695 to 16.718) <0.001
aCI, confidence interval; HR, hazard ratio.
Figure 2 Impact of AJCC Seventh Edition N staging (A) and MLNR sta
underwent radical resection. (A) The disease-specific survival rates of N0
65.5%, 42.9%, 22.2% and 0, respectively (N0 vs N1, P = 0.017; N1 vs N2, P =
MLNR0, MLNR1, MLNR2 and MLNR3 patients were 65.5%, 45.0%, 21.1% and
P = 0.033; MLNR2 vs. MLNR3, P = 0.015).
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was not significant (r = −0.140, P = 0.110) (Figure 3B).ROC curve for disease-specific survival prediction
The area under the curve (AUC) ratios were 0.731 (95%
CI: 0.647 to 0.816, P < 0.001) for AJCC Seventh Edition
N staging and 0.737 (95% CI: 0.653 to 0.821, P < 0.001)
for the MLNR staging, indicating that the MLNR staging
was similar to the AJCC Seventh Edition N staging system
and could be used as an alternative prognostic staging tool
for ESCC patients (Figure 4).Discussion
The aging of the population and a longer life expectancy
have led to more elderly patients with cancers being
referred for treatment. For many of them, in particular
for those with EC, surgery remains the mainstay of treat-
ment. There is no established cutoff to define a patient
as “elderly” in relation to surgery, but most studies avail-
able to date have set the age limit at 70 years [7,8]. In
our study, we determined the prognostic value of MLNR
compared with N staging in EC patients older than
70 years of age. Our results suggest that MLNR might
be a valuable prognostic factor of survival in elderly
patients in EC. We conclude that MLNR staging predicts
survival after EC similar to the AJCC Seventh Edition N
staging classifications and should be considered as an
alternative to current pathological N staging. To the bestging (B) on disease-specific survival of ESCC patients who
, N1, N2 and N3 patients in AJCC Seventh Edition N staging were
0.050; N2 vs N3, P < 0.001). (B) The disease-specific survival rates of
0, respectively (MLNR0 vs. MLNR1, P = 0.026; MLNR1 vs MLNR2,
Figure 3 Correlation related to MLNR. (A) There was a positive correlation between the MLNR and NMLN (r =0.914, P < 0.001). (B) A negative
correlation between MLNR and TLN, however, was not significant (r = −0.140, P = 0.110).
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evaluate the value of MLNR vsAJCC Seventh EditionN
staging in elderly patients with EC.
The ratio of metastatic to total lymph nodes (that is,
the MLNR) has been shown to be a prognostic factor in
EC, but the value of MLNR that is most predictive ofFigure 4 ROC curve for survival prediction. The ROC for MLNR
staging is represented by the blue line with an AUC = 73.7%, and
the ROC for AJCC Seventh Edition N staging is represented by the
green line with an AUC = 73.1%.survival is being debated. Most of the studies published to
date concerning the MLNR and survival have been based
on the AJCC Sixth Edition classification system [3-5].
Furthermore, in terms of MLNR and survival, some
studies have classified the MLNR into three groups,
whereas other studies have used two classifications. In
our study, the MLNR was categorized by deciles into 0
(MLNR0), >0 to <0.1 (MLNR1), 0.1 to <0.3 (MLNR2) and
≥0.3 (MLNR3), based on the AJCC Seventh Edition classi-
fication system. We developed the MLNR intervals on the
basis of our data to provide clinically relevant MLNR
strata while probing to identify the subset of MLNR with
the greatest predictive potential. In our study, the disease-
specific survival rates of MLNR0, MLNR1, MLNR2
and MLNR3 patients were 65.5%, 45.0%, 21.1% and 0,
respectively (MLNR0vs MLNR1, P = 0.026; MLNR1
vs MLNR2, P = 0.033; MLNR2 vs MLNR3, P = 0.015).
Wilson et al. [9] classified 144 patients into 4 groups
according to MLNR: 0, ≤25%, >25 to ≤50% and > 50%.
Althoughan increasing MLNR was linearly associated with
a worsening 5-yr survival rate in their study, statistical
significance was not achieved (P = 0.153). Bogoevski et al.
[10] also classified 235 patients into four categories
according to MLNR: 0, <11%, 11% to 33% and >33%,
which is similar to our findings.
The question of how many lymph nodes should be
dissected has been a point of debate in previous studies.
Rizk et al. [11] reported that the prognosis of patients after
esophagectomy worsens significantly after four or more
lymph nodes have metastases, irrespective of T stage.
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18 nodes as the minimum number of resectable lymph
nodes, whereas Peyre et al. [14] recommended a minimum
of 23 regional lymph nodes. Attendees at a consensus
conference of experts in 1995 suggested that accurate
pathological staging of EC requires resection of at
least 15 nodes [15]. The International Union Against
Cancer (UICC) and AJCC have proposed that at least
sixlymph nodes should be removed during resection
of EC. Hu et al. [16] used a cutoff of six removed lymph
nodesas the definition of adequate nodal dissection. Their
results showed that patients with six or more lymph nodes
dissected had a higher rate of positive lymph nodes
identified (46.9% vs 30.3%) and an improvement in
overall survival that was statistically significant in
pathologically node-negative patients. Accordingly, we
excluded patients who had fewer than sixdissected
lymph nodes (range: 6 to 61). In our study, we did not find
any survival rate difference when using a cutoff of 18
nodes (42.6% vs 44.7%, P = 0.741).
In the present study, the correlation related to MLMR
was determined. As expected, we found that there was a
positive correlation between MLNR and NMLN
(r = 0.914, P < 0.001). There was a negative correlation be-
tween MLNR and TLN; however, the correlationwas not
significant (r = −0.140, P = 0.110). ROC curves were plot-
ted to verify the accuracy of MLNR staging and N staging
for survival prediction. The AUCs were 0.731 for the 2010
AJCC N staging and 0.737 for the MLNR staging, indicat-
ing that the MLNR staging was similar to the AJCC
Seventh Edition N staging system and could be used as an
alternative prognostic staging tool for EC patients.
The potential limitations of the present study include
the relatively small number of patients, the use of a
retrospective analysis and the short duration of the mean
follow-up. In addition, because the study used data from a
single institution but with different pathologists and differ-
ent surgeons, there may have been a lack of uniformity in
measurement methods. Furthermore, owing to the limited
number of patients in EC, our analysis may contain type I
or type II errors. The results of the study should therefore
be regarded with caution. Further studies are needed
to explore its long-term effect.
Conclusion
In summary, our study suggests that the survival rate of
elderly patients with ESCC can be categorized into four
groups: MLNR0 (0), MLNR1 (>0 to ≤0.1), MLNR2 (>0.1
to ≤0.3) and PLNR3 (>0.3). We conclude that MLNR is
an independent predictor of survival in elderly patients
undergoing esophagectomy for EC. MLNR staging
predicts survival after EC similarly to the 2010 AJCC N
classifications and should be considered as an alternative
to current pathological N staging.Competing interests
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